Pharma Focus Asia

Mitsubishi Tanabe Pharma Announces Approval of RADICAVA® Oral Suspension in Switzerland

Wednesday, May 10, 2023

Mitsubishi Tanabe Pharma Corporation announced that its wholly owned subsidiary, Mitsubishi Tanabe Pharma obtained the approval from Authority of Switzerland (Swissmedic) to RADICAVA® Oral Suspension for the indication of amyotrophic lateral sclerosis. RADICAVA® Oral Suspension will be commercialised by MTPD in Switzerland.

RADICAVA® Oral Suspension offers the same efficacy as edaravone for intravenous infusion, a treatment shown in a pivotal trial to help slow the loss of physical function in ALS. RADICAVA® Oral Suspension formulation serves as a new treatment option for ALS patients in order to address unmet needs of people living with ALS.

RADICAVA® Oral Suspension is specifically formulated for patients with ALS and provides a flexible administration option with a 5ml dose taken orally or via feeding tube. One cycle of administration of RADICAVA® Oral Suspension is a total of 28 days, including both the dosing period and the drug-free period, and that cycle is repeated. 

RADICAVA® Oral Suspension are available in bottles and do not require water or solution to administer. RADICAVA® Oral Suspension needs to be refrigerated during the distribution process and in pharmacies, but patients can keep it at room temperature.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Adopting the Power of AI to Drug Development ProjectsROUQETTE - Pharma Virtual LabDUPHAT 2024Thermo Fisher Scientific - Rapid Mycoplasma TestingAsia Healthcare Week 20247th Annual Pharma Project & Portfolio Management 2024CHEMICAL INDONESIA 2024INALAB 2024The Drug Safety Symposium 2024Medlab Middle East 2024ISPE Singapore Affiliate Conference & Exhibition 2024